Brian Young - Novanta Chief Human Resource Officer
| NOVT Stock | USD 149.07 1.32 0.89% |
Executive
Mr. Brian Young serves as Chief Human Resource Officer of the company. Mr. Young brings more than 20 years of human resources leadership experience in both public and private companies serving Original Equipment Manufacturers of Class I, II III medical devices, industrial control technology and advanced materials. From July 2014 to March 2015, Mr. Young served as Global Human Resource Leader for Hollingsworth Vose Company. From September 2011 to November 2013, Mr. Young served as Vice President Human Resource Officer for CIRCOR International, Inc. From September 2010 to August 2011, Mr. Young served as Director Total Rewards for CIRCOR. In addition, from June 2003 to August 2010, Mr. Young served in various leadership roles with Lake Region Medical . Mr. Youngs early career experience was in General Human Resource Management with a specialization in training and development since 2016.
| Age | 55 |
| Tenure | 9 years |
| Address | 125 Middlesex Turnpike, Bedford, MA, United States, 01730 |
| Phone | 781 266 5700 |
| Web | https://www.novanta.com |
Brian Young Latest Insider Activity
Tracking and analyzing the buying and selling activities of Brian Young against Novanta stock is an integral part of due diligence when investing in Novanta. Brian Young insider activity provides valuable insight into whether Novanta is net buyers or sellers over its current business cycle. Note, Novanta insiders must abide by specific rules, including filing SEC forms every time they buy or sell Novanta'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Brian Young over six months ago Novanta exotic insider transaction detected | ||
Brian Young over six months ago Payment of 156 shares by Brian Young of Novanta subject to Rule 16b-3 | ||
Brian Young over six months ago Disposition of 351 shares by Brian Young of Novanta subject to Rule 16b-3 | ||
Brian Young over a year ago Exercise or conversion by Brian Young of 2575 shares of Novanta subject to Rule 16b-3 |
Novanta Management Efficiency
The company has return on total asset (ROA) of 0.0535 % which means that it generated a profit of $0.0535 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0867 %, meaning that it created $0.0867 on every $100 dollars invested by stockholders. Novanta's management efficiency ratios could be used to measure how well Novanta manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.12 in 2025. Return On Capital Employed is likely to gain to 0.1 in 2025. At this time, Novanta's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 499.2 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 106.1 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Steve Savis | ESCO Technologies | N/A | |
| Brian Archbold | Mesa Laboratories | 50 | |
| Inbal Dangur | Vishay Precision Group | N/A | |
| Peter JD | Fortive Corp | 55 | |
| Rafi Uzan | Vishay Precision Group | 58 | |
| Mike Alfred | ESCO Technologies | N/A | |
| Griffin Whitney | Fortive Corp | N/A | |
| Andrew McCauley | Fortive Corp | N/A | |
| Victor III | Fortive Corp | 56 | |
| Kirsten Paust | Fortive Corp | N/A | |
| Elena Rosman | Fortive Corp | N/A | |
| Yaron Kadim | Vishay Precision Group | 60 | |
| Siobhan Andrews | Spectris plc | N/A | |
| Brian CFA | Genasys | N/A | |
| Andrew Heath | Spectris plc | 59 | |
| Rafi Ouzan | Vishay Precision Group | 59 | |
Management Performance
| Return On Equity | 0.0867 | ||||
| Return On Asset | 0.0535 |
Novanta Leadership Team
Elected by the shareholders, the Novanta's board of directors comprises two types of representatives: Novanta inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novanta. The board's role is to monitor Novanta's management team and ensure that shareholders' interests are well served. Novanta's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novanta's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ray Nash, Corporate IR | ||
| Michele Welsh, General Secretary | ||
| Sarah Betadam, Chief Officer | ||
| Heinrich Dreyer, Group Solutions | ||
| Peter Chang, Corporate Officer | ||
| Brian Young, Chief Human Resource Officer | ||
| Charlie Webster, Executive Chain | ||
| Matthijs Glastra, CEO Chairman | ||
| John II, Chief Controller | ||
| Anna Fain, Equity Diversity | ||
| Chuck Ravetto, Group Group | ||
| John Lesica, CoChief Solutions | ||
| Robert Buckley, Chief Officer |
Novanta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novanta a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0867 | ||||
| Return On Asset | 0.0535 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 5.73 B | ||||
| Shares Outstanding | 35.92 M | ||||
| Shares Owned By Insiders | 0.85 % | ||||
| Shares Owned By Institutions | 99.15 % | ||||
| Number Of Shares Shorted | 1.76 M | ||||
| Price To Earning | 126.20 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Novanta Stock Analysis
When running Novanta's price analysis, check to measure Novanta's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novanta is operating at the current time. Most of Novanta's value examination focuses on studying past and present price action to predict the probability of Novanta's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novanta's price. Additionally, you may evaluate how the addition of Novanta to your portfolios can decrease your overall portfolio volatility.